Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

Recent News

FDA Brief: New Guidance for Industry on Tissue-Agnostic Drug Development
Rechallenge With Osimertinib Plus Entrectinib in Lung Cancer With NTRK Fusion: Case Report
Are Kinase Inhibitors the Future for Patients With Refractory Thyroid Cancer?
Prevalence of NTRK Gene Fusions in a Real-World Canadian Setting
Detecting NTRK Gene Fusions in Metastatic Triple-Negative Breast Cancer: Case Report
Research Focuses on Identifying Genetically Matched Therapies for Salivary Gland Cancer
5 Years After Larotrectinib Treatment, MSK Patient Celebrates First Day of Kindergarten
Larotrectinib, Entrectinib, and Metastatic Cancers With NTRK Gene Fusion: Focus on Partitioned Survival Modeling
Can Semiconductor Sequencing Be of Use in Detecting Actionable Fusions in Solid Tumors?
Profiling Patients With NTRK Gene Fusion–Positive Cancer: UK Genomes Project
Real-World Survival Outcomes in Patients With NTRK Fusion–Positive or –Negative Solid Tumors
ESMO 2022: Frequency of Molecular Targets in Salivary Gland Carcinomas
Unique Presentation and Spread of Congenital Infantile Fibrosarcoma With NTRK::ETV6 Fusion
Genetic Characteristics of Patients Who Have Solid Tumors With ALK/ROS1/NTRK Fusions
Larotrectinib for TRK Fusion–Positive Salivary Gland Tumors
RNA-Based Assay Identifies NTRK Gene Fusions in a Pan-Cancer Setting
Pan-TRK Immunohistochemistry for NTRK Gene Fusion Screening of Solid Tumors
Use of Entrectinib in Treatment of Malignant Glioneuronal Tumors: Case Report
NTRK Gene Fusion Linked to Case of Infantile Fibrosarcoma
TRK Expression and Molecular Characteristics of Gene Fusions in Primary Liver Carcinomas
Genetic Sequencing of Colorectal Cancer: Identifying NTRK Fusions and/or Other Mutations
Research and Development Partnership to Study Next-Generation Kinase Inhibitors
NTRK3 Fusion–Positive Sarcoma: 6-Year-Old Girl Treated With Larotrectinib and Radiotherapy
ASCO 2022: Update on Use of Entrectinib for Advanced NTRK Fusion–Positive Solid Tumors
ASCO 2022: Health-Related Quality of Life With Larotrectinib for TRK-Fusion Cancer
FDA Brief: Companion Diagnostic for Entrectinib Receives Approval
ASCO 2022: Expanded Cohort Update on Larotrectinib for NTRK Fusion–Positive Lung Cancer
ASCO 2022: How Common Are NTRK Alterations in Colorectal Cancer?
NTRK Fusion–Positive NSCLC: Challenges in Detection Methods
Spotlight

JNCCN Spotlights

View More
Advertisement

Resources

For Cancer Care

View More
Sections
360 Hub
NCCN Resources
Copyright© 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.